These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2489968)

  • 1. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
    Wolf JA; Grimm EA
    Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive cellular immunotherapy of cancer: future perspectives.
    Stevenson HC
    Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular immunotherapy of cancer].
    Kawakami Y
    Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques.
    Yannelli JR; Jadus MR; Beckner S; Lacerna LV; Oldham RK
    Immunol Ser; 1989; 48():191-206. PubMed ID: 2488322
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
    Peyret C
    J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1992; 13():191-204. PubMed ID: 1389910
    [No Abstract]   [Full Text] [Related]  

  • 14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of metastatic melanoma with interleukin-2].
    Chosidow O; Guillaume JC
    Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive immunotherapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1994; 15():213-25. PubMed ID: 7779587
    [No Abstract]   [Full Text] [Related]  

  • 18. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
    Clark J; Longo DL
    Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
    [No Abstract]   [Full Text] [Related]  

  • 19. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer.
    Yannelli JR
    J Immunol Methods; 1991 May; 139(1):1-16. PubMed ID: 2040807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.